Drug Trial Radar · NCT06695897
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
May 28, 2025
Primary completion
Jun 1, 2027
Study completion May 29, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Nov 19, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with respect to their medical history, socio-demographic and disease characteristics, comorbidities (including type 2 inflammatory and atopic conditions), concomitant therapies and prior EoE treatments. Furthermore, this NIS aims to describe the long-term effectiveness of dupilumab for the treatment of EoE as assessed by the treating physician and reported by the patient, and its effect on health-related quality of life (HRQoL) during an individual observational period of two years. In addition, data on real-world use patterns and long-term safety data of dupilumab treatment for EoE will be collected.
Conditions
- Eosinophilic Esophagitis
Interventions
DupilumabDrug
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Descriptive statistical analysis of medical history characteristicsTime frame: At baseline
- Descriptive statistical analysis of socio-demographic characteristicsTime frame: At baseline
- Descriptive statistical analysis of disease characteristicsTime frame: At baseline
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number: 0000004
Berlin, Germany · Recruiting
Investigational Site Number: 0000009
Aschaffenburg, Bavaria, Germany · Recruiting
Investigational Site Number: 0000014
Augsburg, Bavaria, Germany · Recruiting
Investigational Site Number: 0000001
Dachau, Bavaria, Germany · Recruiting
Investigational Site Number: 0000012
Erlangen, Bavaria, Germany · Recruiting
Investigational Site Number: 0000005
Giessen, Hesse, Germany · Recruiting
Investigational Site Number: 0000011
Wetzlar, Hesse, Germany · Recruiting
Investigational Site Number: 0000013
Osnabrück, Lower Saxony, Germany · Recruiting
Investigational Site Number: 0000002
Weyhe-Kirchweyhe, Lower Saxony, Germany · Recruiting
Investigational Site Number: 0000007
Bochum, North Rhine-Westphalia, Germany · Recruiting
Investigational Site Number: 0000003
Burbach, North Rhine-Westphalia, Germany · Recruiting
Investigational Site Number: 0000006
Guelders, North Rhine-Westphalia, Germany · Recruiting
Investigational Site Number: 0000010
Münster, North Rhine-Westphalia, Germany · Recruiting
Investigational Site Number: 0000008
Leipzig, Saxony, Germany · Recruiting
Investigational Site Number: 0000015
Magdeburg, Saxony-Anhalt, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.